Abstract
Tiotropium, a longer acting anticholinergic bronchodilator, has been widely used for treatment of chronic obstructive pulmonary disease (COPD). To improve the therapeutic effect of tiotropium, we developed various inhalation microparticular formulations of tiotropium using starch, hyaluronate, bovine serum albumin (BSA), and poly(lactide-co-glycolide) (PLGA). All formulations showed ~90 % inhalation efficiency in the lung epithelium of BALB/c mice after initial administration. Interestingly, when compared to other formulations using starch, hyaluronate, and BSA, the inhalation formulation of tiotropium using PLGA showed longer drug residence (up to 7 days) in in vivo lung epithelium. We believe that this microparticle system is expected to improve the treatment efficacy for the patients with COPD by maintaining drug therapeutic effect during the extended period after initial inhalation.
| Original language | English |
|---|---|
| Pages (from-to) | 71-74 |
| Number of pages | 4 |
| Journal | Journal of Pharmaceutical Investigation |
| Volume | 43 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2013 |
Bibliographical note
Funding Information:Acknowledgments This work was financially supported by the GRRC Program of Gyeonggi Province [GRRC 2012-B01, Development of industrial nano-/micro-sized biomaterials for high performance drug release control].
Keywords
- Chronic obstructive pulmonary disease
- Inhalant formulation
- PLGA
- Tiotropium
Fingerprint
Dive into the research topics of 'Development of tiotropium inhalation formulations for the treatment of chronic obstructive pulmonary disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver